Tecentriq 840 MG/14 ML vial 14ML
Ended Awarded Last action
- Contract number
- SPE2DR26FG1ZH
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $17,925
Award facts
- Contract value 100% obligated
- $17,925.08 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 8, 2025, for the supply of Tecentriq (atezolizumab) 840 mg/14 mL vials, a monoclonal antibody cancer immunotherapy medication. This firm fixed-price delivery order, valued at $17,925.08, is a non-competitive set-aside award and is scheduled for completion by December 30, 2025. The pharmaceutical will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical prime vendor agreement valued at $999,999,999.00 and extending through December 2026, which enables the contractor to supply a broad range of pharmaceutical products and medical supplies to support military and federal healthcare programs worldwide.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement, particularly for the Defense Health Agency and other military healthcare systems. The company maintains an extensive portfolio of federal contracts with DLA covering diverse pharmaceutical commodities including specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains. All of the company's reviewed contract awards have been competitively awarded with firm fixed-price terms, demonstrating its capability to meet federal procurement requirements at various transaction values. This delivery order for Tecentriq represents one of numerous medical supply transactions supporting the department's ongoing pharmaceutical needs.
Quick answers
Who was awarded contract SPE2DR26FG1ZH?
SPE2DR26FG1ZH was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on December 8, 2025.
How much is contract SPE2DR26FG1ZH worth?
The government has obligated $17,925 on SPE2DR26FG1ZH.
Is contract SPE2DR26FG1ZH an order under another contract?
Yes. SPE2DR26FG1ZH is a delivery order under SPE2DR25D3016, an indefinite delivery contract.
Was contract SPE2DR26FG1ZH competed?
The extent of competition for SPE2DR26FG1ZH was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award